Cardiology
From the Journals
MIS-C cardiac evaluation requires more than EF
From the Journals
Sleep disorders may be undetected precursors for cardiometabolic disease in U.S. Latinos
Clinicians should consider screening their patients at risk for hypertension and diabetes for both sleep-disordered breathing and insomnia.
Conference Coverage
LoDoCo2: Added steam for colchicine as secondary prevention
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
From the Journals
Statins linked to reduced mortality in COVID-19
A pooled analysis of available data suggest moderate- to high-intensity statin therapy may be beneficial in patients with COVID-19, researchers...
Conference Coverage
Nightmares: An independent risk factor for heart disease?
Those who had nightmares two or more times per week had significantly increased risks for hypertension, MI, or other heart problems.
Conference Coverage
IMPACT-AFib: Single mailing fails to budge oral anticoagulant uptake for AFib
Researchers examined whether a minimal intervention – a single educational mailing – could boost oral anticoagulant use among AFib patients. It...
Conference Coverage
First randomized trial reassures on ACEIs, ARBs in COVID-19
The BRACE CORONA study found no difference in key outcomes between patients continuing versus stopping their medication.
Conference Coverage
ESC’s revised NSTE-ACS guidelines embrace hsT, personalized anti-ischemia treatments
Conference Coverage
Evolocumab safe and effective in pediatric FH
The PCSK9 inhibitor lowered LDL cholesterol by 38% vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the...
Conference Coverage
Gut bacteria linked to cardiovascular, other health conditions
“Microbiota and their metabolites ... could serve as potential therapeutic targets for the maintenance of health and prevention and treatment of...
News
Two PR employees at FDA fired after plasma therapy controversy
The warnings by two public relations experts at the FDA against overpromoting convalescent plasma as a treatment for COVID-19 reportedly led to...